PAION AG : Confirmation of calendar reassures
>A cash position of € 24.5m, 2020 guidance maintained - Paion this morning reported its 9M 2020 results and took this opportunity to recap on its clinical and regulatory activity. First, we would underscore that the German biotech has a cash position of € 24.5m well above that of H1 2020 (vs € 12.4m at end-June). This increase is mainly attributable to milestone payments linked to the approval of remimazolam in the US. The main item of expenditure remains R&D cos...Paion is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focusing on developing and commercializing drugs to be used in out-patient and hospital-based anesthesia, sedation and critical care services. Co.'s key compound is Remimazolam, an intravenous ultra short-acting and controllable anesthetic/sedative drug candidate in advanced stages of development for use in procedural sedation and general anesthesia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.